within Pharmacolibrary.Drugs.ATC.A;

model A03AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.0004333333333333333,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015333333333333334,
    Tlag           = 720
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Trimebutine is a spasmolytic agent acting primarily on the digestive tract. It is used for the treatment of irritable bowel syndrome and other functional gastrointestinal disorders. The drug acts as a peripheral mu-opioid receptor agonist with antimuscarinic properties. While trimebutine has been widely used in some countries (e.g., France, Japan) for gut motility disorders, it is not approved in the United States and various other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Cho, KH, et al., &amp; Park, YJ (2010). Development of a novel combination tablet containing trimebutine maleate and mosapride citrate for the treatment of functional dyspepsia. <i>International journal of pharmaceutics</i> 400(1-2) 145–152. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2010.08.047&quot;>10.1016/j.ijpharm.2010.08.047</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20826201/&quot;>https://pubmed.ncbi.nlm.nih.gov/20826201</a></p></li><li><p>Lavit, M, et al., &amp; Houin, G (2000). Determination of trimebutine and desmethyl-trimebutine in human plasma by HPLC. <i>Arzneimittel-Forschung</i> 50(7) 640–644. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1300264&quot;>10.1055/s-0031-1300264</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10965422/&quot;>https://pubmed.ncbi.nlm.nih.gov/10965422</a></p></li><li><p>Aktas, A, et al., &amp; Mentes, T (1999). The effect of trimebutine maleate on gastric emptying in patients with non-ulcer dyspepsia. <i>Annals of nuclear medicine</i> 13(4) 231–234. DOI:<a href=&quot;https://doi.org/10.1007/BF03164897&quot;>10.1007/BF03164897</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10510878/&quot;>https://pubmed.ncbi.nlm.nih.gov/10510878</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03AA05;
